Abstract

Cancer care through molecular diagnostics: Addressing papillary thyroid cancer Oliver Bathe from the University of Calgary and Qualisure Diagnostics, walks us through addressing the surge in papillary thyroid cancer incidence by refining cancer care through molecular diagnostics. The incidence of papillary thyroid cancer (PTC) is rising by more than 6% in most developed countries, mainly due to increased early detection. While early detection is generally beneficial in cancer care, PTC presents a unique challenge. Because it is rarely life-threatening, the discovery of small, early-stage tumors raises the question of how to manage them without causing harm through overtreatment.